Ad5.F35-hGUCY2C-PADRE vaccine (Thomas Jefferson University)

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug NameAd5.F35-hGUCY2C-PADRE vaccine (Thomas Jefferson University)
Drug Alias NameAd5/F35-hGCC-PADREAdenovirus 5/F35-HGCC-PADRE
ClassificationVaccines > Application > Therapeutic vaccineCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsColorectal NeoplasmsAdenocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThomas Jefferson University
China Registration ClassN/A

Develop Information

Active CompaniesThomas Jefferson University
Inactive CompaniesN/A
Active IndicationsColorectal NeoplasmsAdenocarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A